A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis

Condition:   Non-Alcoholic Steatohepatitis
Interventions:   Drug: EDP-305 Dose 1;   Drug: EDP-305 Dose 2;   Drug: Placebo
Sponsors:   Enanta Pharmaceuticals;   ICON Clinical Research;   Triangle Biostatistics
Recruiting
ClinicalTrials.gov: Liver | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

March 13, 2018 / by / in
Comments